Study on the Action of Natural Products on Candida Albicans Crops
Olimpia-Nicoleta Moroianu,
Nelu-Doru Popescu,
Alina Raluca Ursu,
Natalia Rosoiu
Issue:
Volume 8, Issue 3, September 2022
Pages:
27-32
Received:
22 June 2022
Accepted:
9 July 2022
Published:
15 August 2022
DOI:
10.11648/j.ijbecs.20220803.11
Downloads:
Views:
Abstract: The paper aims to highlight the action of some natural substances on Candida albicans crops. The observations were made using different concentrations of substances that acted under conditions of constant temperature and different time intervals. Thus, in the present study we investigated the inhibition of candida development by using essential oils such as: tea tree, oregano, black cumin, coriander, rosemary, juniper, marigold tincture and a graviola capsule for a period of 48 h; for the 72 h we used essential oils, namely: sage, mint, geranium, aloe vera, thyme, tinctures (such as: tincture of marigold, propolis, plantain and chamomile), graviola capsules, colloidal solutions of Ag ions super concentrate, of Au and Ag ions), Lady's Water, Bitter (from 50 plants with ganoderma, respectively Swedish drops), apple cider vinegar and 9% wine vinegar. For the proposed study we put all these substances on dishes with samples of Candida albicans and let them act for 48 hours or 72 hours to understand what is happening. At the end of the experiments we interpreted the results obtained and issued the necessary conclusions, ie we could know for sure if these substances used in the research study are good or not to be able to eliminate Candida albicans from the human body infected with candida.
Abstract: The paper aims to highlight the action of some natural substances on Candida albicans crops. The observations were made using different concentrations of substances that acted under conditions of constant temperature and different time intervals. Thus, in the present study we investigated the inhibition of candida development by using essential oil...
Show More
Driver Mutations in Non-Small Cell Lung Cancer: Utility of Liquid Biopsy
Andrew Friday,
Khaled Alhamad,
Gene Grant Finley,
Robin Raquel Rodriguez,
Herman Lo,
Aaron Weidman,
Zachary Otaibi,
Ashish Sethi,
Suneera Bhatia
Issue:
Volume 8, Issue 3, September 2022
Pages:
33-39
Received:
8 August 2022
Accepted:
29 August 2022
Published:
5 September 2022
DOI:
10.11648/j.ijbecs.20220803.12
Downloads:
Views:
Abstract: Non-small Cell Lung Cancer (NSCLC) has become the most prominent example demonstrating the importance of targeted therapy in cancer treatment. Up to 25% of patients with non-squamous NSCLC (nsNSCLC) harbor driver mutations which are responsible for the malignancy. For these patients, oral targeted drugs directed against the mutated gene yield better outcomes than chemotherapy or immunotherapy. Consequently, assessing the tumor for driver mutations has become standard of care in managing nsNSCLC. However, in 20% of lung cancer patients, the tissue biopsy is either unobtainable or insufficient to assay. In these circumstances, analyzing circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) from the blood can reveal the driver mutations. A prospective study was conducted with Biocept, to evaluate the clinical utility of a single gene assay using ctDNA and CTCs in patients with advanced NSCLC. Here, we report the comparison between biomarker expression of the tumor tissue and liquid biopsy of matched samples of 40 unique patients. Methods: Matched liquid biopsy and tumor tissue was analyzed from forty unique patients with stage III and IV NSCLC for EGFR, KRAS, BRAF, ALK, and ROS-1. Tissue was analyzed by Next Generation Sequencing (NGS), whereas peripheral blood samples for liquid biopsy was analyzed using circulating tumor DNA (ctDNA) for EGFR, KRAS, and BRAF mutations, and circulating tumor cells (CTCs) for ALK and ROS-1 mutations. Results: 80% of the patients (32/40) received both tissue biopsy and liquid biopsy analysis. The concordance between EGFR, KRAS, BRAF, ALK and ROS-1 between tumor tissue and liquid biopsy was 86%. Furthermore, liquid biopsy demonstrated a higher rate of conclusive results compared to tissue biopsy and led to a change in treatment for in 4 of the 40 patients. Conclusion: This works suggests that tissue and liquid biopsy can be complementary, and liquid biopsy can inform the course of treatment when a tissue biopsy is not available.
Abstract: Non-small Cell Lung Cancer (NSCLC) has become the most prominent example demonstrating the importance of targeted therapy in cancer treatment. Up to 25% of patients with non-squamous NSCLC (nsNSCLC) harbor driver mutations which are responsible for the malignancy. For these patients, oral targeted drugs directed against the mutated gene yield bette...
Show More
